Beam, Inc. (BEAM) Misses Q3 EPS by 28c, Revenues Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
November 7, 2022 6:30 AM ESTPatient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution
IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa
BEAM-302 Nominated as Development Candidate for Treatment of Alpha-1 Antitrypsin Deficiency; Targeting Durable Gene Correction Designed to Address Both Lung and Liver Disease
New Data Highlighting Enhanced Conditioning Approach for Hematologic Transplant (ESCAPE) to be Presented at ASH
Ended Third Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities
CAMBRIDGE,... More
